




Product Introduction

BMS-833923

BMS-833923 is an orally bioavailable **Smoothened** antagonist. Phase 2.

Technical Data:

Molecular Weight (MW):	473.57	
Formula:	C ₃₀ H ₂₇ N ₅ O	
Solubility (25°C)	DMSO 95 mg/mL	
* <1 mg/ml means slightly soluble or insoluble:	Water <1 mg/mL	
	Ethanol <1 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder 6 months -80°C in DMSO	
CAS No.:	1059734-66-5	

Biological Activity

BMS-833923 reduces hedgehog pathway activity, decreases cell proliferation and induces apoptosis via the intrinsic pathway in esophageal adenocarcinoma (EAC) cell lines. [2] BMS-833923 dose-dependently affects canonical and prostate hedgehog signature gene transcription in vitro. [3]

References

[1] Tang JY, et al. Semin Cutan Med Surg. 2011, 30(4 Suppl), S14-18.

[2] Zaidi AH, et al. Cancer Invest. 2013, 31(7), 480-489.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

[3] Wilkinson SE, et al. Prostate. 2013, 73(16), 1810-1823.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.